Biopharma News

Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.

GSK and Save the Children announce criteria for awards that recognize innovation in healthcare for the world"s poorest children.

Cytovance Biologics completes GMP manufacture of ARMO BioSciences' lead product.

Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.

Shire reports that AbbVie offer undervalued company.

FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.

Novartis facility becomes the first US site licensed by the FDA to produce cell-culture influenza vaccines.

The new mAb manufacturing facility in Switzerland will supply material for clinical development.

Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.

PharmaCell has finalized its purchase of the cell therapy production facility from TiGenix.

Aastrom acquires Sanofi's CTRM business unit for $6.5 million.

Alexion initiates a voluntary nationwide recall of certain lots of soliris (eculizumab) concentrated solution for intravenous infusion because of visible particulate matter in a single lot.

GSK selects Genedata Biologics as an R&D data management and workflow-support platform.

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

Kymab receives $40 million investment for clinical development of antibody therapeutics.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals invest $1 million each in Cumberland Emerging Technologies.

Boehringer Ingelheim and Connexios Life Sciences announce global research collaboration agreement for AMPK agonists.

Agenus and Merck work together to advance immune-oncology programs.

Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.